The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
about
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host.Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
P2860
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@en
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@nl
type
label
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@en
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@nl
prefLabel
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@en
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@nl
P2093
P2860
P1476
The combination of trastuzumab ...... nt cell-mediated cytotoxicity.
@en
P2093
György Vereb
Gábor Tóth
János Szöllősi
László Simon
Yosef Yarden
Árpád Szöőr
P2860
P304
P356
10.1080/19420862.2016.1204503
P577
2016-07-05T00:00:00Z